LONDON, October 31, 2012 /PRNewswire/ --
GlaxoSmithKline released third quarter results today with Finance Director Simon Dingemans saying the pharma group was on course to deliver growth in Q4 and sales "broadly in line" with the previous year.
In a video interview Mr Dingemans said while factors such as costs from disposals and weak European sales had added to a difficult quarter where total sales were down 5%, performances from promoted and new products plus R&D developments meant shareholders saw dividends up 6% year-on-year.
"I think we're pleased with the progress that the growth drivers and the core strategic businesses are making and I think overall that leaves us feeling that we have good momentum going into the fourth quarter."The interview and transcript are available now on http://www.cantos.com/company/GlaxoSmithKline. MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email email@example.com or phone +44-207-936-1352. SOURCE GlaxoSmithKline
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts